CRYSTALLINE AND NON CRYSTALLINE FORMS OF SGLT2 INHIBITORS

摘要

The present invention provides amorphous forms and the crystalline complexes of SGLT2 inhibitors as a novel material in particular in pharmaceutically acceptable form. The crystalline forms of SGLT2 inhibitor canagliflozin are designated as Forms CS1 CS2 CS3 CS4 and CS5.